Bioporto AS
2P4
Company Profile
Business description
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.
Contact
Tuborg Havnevej 15
Ground Floor
HellerupDK-2900
DNKT: +45 45290000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
38
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,195.50 | 10.00 | 0.12% |
| CAC 40 | 7,916.08 | 74.03 | -0.93% |
| DAX 40 | 22,461.52 | 217.22 | -0.96% |
| Dow JONES (US) | 41,583.90 | 715.80 | -1.69% |
| FTSE 100 | 8,658.85 | 7.27 | -0.08% |
| HKSE | 23,426.60 | 152.20 | -0.65% |
| NASDAQ | 17,322.99 | 481.04 | -2.70% |
| Nikkei 225 | 37,120.33 | 679.64 | -1.80% |
| NZX 50 Index | 12,287.46 | 18.33 | -0.15% |
| S&P 500 | 5,580.94 | 112.37 | -1.97% |
| S&P/ASX 200 | 7,982.00 | 13.00 | 0.16% |
| SSE Composite Index | 3,351.31 | 22.44 | -0.67% |